AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11937315
Drug: Rubitecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubitecan 1.5 mg/m2 after a high calorie breakfast
Trial: 11937315
Drug: Rubitecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubitecan 1.5 mg/m2/day under fasting conditions for 5 consecutive days per week until disease progression
Trial: 10432133
Drug: Soy supplementation
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplementation (60 g of soy powder daily for 3 months)
Trial: 1835587
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with buserelin (CAF regimen)
Trial: 1835587
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with buserelin (CMF regimen)
Trial: 1835587
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with buserelin
Trial: 6123719
Drug: Control (Tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Tetracycline ophthalmic ointment)
Trial: 31389614
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with adrenaline (5 μg.ml-1)
Trial: 27090108
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1000 mg/day)
Trial: 21231862
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 5/30 mg oxycodone HCl/niacin tablets
Trial: 21231862
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 7.5/30 mg oxycodone HCl/niacin tablets
Trial: 12948274
Drug: Enteric-coated Thai
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated Thai garlic extract tablet (1.12% allicin or 5.6 mg/tablet) once daily for 12 weeks
Trial: 1543812
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole in the morning
Trial: 1543812
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole in the evening
Trial: 27780567
Drug: Experimental ONS
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental ONS (EONS, 20 g protein; 499 IU vitamin D3; 1.5 g CaHMB)
Trial: 27780567
Drug: Control ONS
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ONS (CONS, 14 g protein; 147 IU vitamin D3)
Trial: 15500496
Drug: Controlled ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ventilation with muscle relaxants and inhalation anesthesia
Trial: 3317346
Drug: Yeast-derived hepatitis
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived hepatitis B vaccine (10, 20, 40 micrograms)
Trial: 3317346
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including both yeast-derived and plasma-derived vaccines)
Trial: 30786916
Drug: Induction carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction carbon ion radiotherapy (CIRT) boost followed by 60 GyE of proton irradiation with concurrent temozolomide (TMZ) at 75 mg/m2.
Trial: 30786916
Drug: CIRT boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRT boost (dose determined in Phase I of this trial) followed by 60 GyE of proton irradiation with concurrent TMZ.
Trial: 30786916
Drug: 60 GyE
RxNorm normalized name: DIMETHICONE 0.6 g in 100 mL TOPICAL SHAMPOO [GYEOL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 GyE (2 GyE per fraction) of proton irradiation with concurrent TMZ (control arm).
Trial: 27272673
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (HES) solution at 24 ml·kg·h
Trial: 27272673
Drug: Acetated Ringer's
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer's solution at 24 ml·kg·h
Trial: 27272673
Drug: Acetated Ringer's
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer's solution at 2 ml·kg·h
Trial: 24565384
Drug: Midazolam 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.025 mg kg(‐1) intravenously
Trial: 15738352
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clopidogrel with eptifibatide
Trial: 15738352
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clopidogrel without eptifibatide
Trial: 15738352
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg clopidogrel without eptifibatide
Trial: 7657850
Drug: 200-mg oral
RxNorm normalized name: lesinurad
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200-mg oral controlled-release morphine sulfate tablet with naltrexone blockade
Trial: 7657850
Drug: two 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 100-mg MSC tablets
Trial: 28703903
Drug: Nemolizumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 0.1 to 3 mg/kg as a single dose once every 4 weeks or 2 mg/kg once every 8 weeks
Trial: 25891232
Drug: Daily or
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily or nearly daily drinking
Trial: 21251985
Drug: Tanezumab 50μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 50μg/kg administered on Days 1 and 56 with subsequent doses at 8-week intervals (up to a total of eight infusions)
Trial: 19117313
Drug: EMLA Cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA Cream (EC)
Trial: 19117313
Drug: Placebo (lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lubricant ointment)
Trial: 15011220
Drug: Standard advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard advanced cardiac life support (ACLS) intervention with early empiric administration of bicarbonate (1-mEq/kg dose)
Trial: 15011220
Drug: Standard advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard advanced cardiac life support (ACLS) intervention without early empiric administration of bicarbonate
Trial: 11426094
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg intravenously at the time of dural closure
Trial: 9437202
Drug: Cholesterol-lowering therapies
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering therapies
Trial: 8290902
Drug: Cefpirome 1
RxNorm normalized name: cefpirome 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 1 g bid
Trial: 8290902
Drug: Ceftazidime 1
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1 g bid
Trial: 8290902
Drug: Cefpirome 2
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 2 g bid
Trial: 8290902
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g tid
Trial: 8290902
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g bid
Trial: 3326634
Drug: Pindolol, 10
RxNorm normalized name: Pindolol, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol, 10 mg twice daily
Trial: 25393089
Drug: Thermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal therapy (sulphurous water insufflation)
Trial: 23611571
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg INFS (Treatment A)
Trial: 23611571
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg INFS (Treatment B)
Trial: 23611571
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg INFS (Treatment C)
Trial: 8701045
Drug: artesunate 600
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: artesunate 600 mg followed by mefloquine 500 mg
Trial: 8701045
Drug: mefloquine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mefloquine 1000 mg
Trial: 1735009
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) 37.5 mg/m2 (regimens A and B) or 75 mg/m2 (regimens C and D) + Hexamethylmelamine (HMM) 200 mg/m2 orally daily on days 8‐21
Trial: 1735009
Drug: Pyridoxine 300
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine 300 mg/m2 orally on Days 1‐21 (regimens B and D)
Trial: 6547795
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (specific type not mentioned)
Trial: 30782764
Drug: ToyBox obesity
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ToyBox obesity prevention intervention; details on dosage and duration not available
Trial: 28681171
Drug: R/D/E (ridaforolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R/D/E (ridaforolimus 10 mg QD 5 ×/week, dalotuzumab 10 mg/kg/week, exemestane 25 mg/day)
Trial: 28681171
Drug: R/E (ridaforolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R/E (ridaforolimus 30 mg QD 5 ×/week, exemestane 25 mg/day)
Trial: 15169576
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of r-hFSH and r-hLH (2:1 ratio)
Trial: 12177098
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg once monthly
Trial: 9875582
Drug: Four-drug oral
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily) + Amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks
Trial: 9875582
Drug: Four-drug oral
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily)
Trial: 7597661
Drug: Eformoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eformoterol 24 micrograms twice daily
Trial: 6357209
Drug: suprofen 400
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: suprofen 400 mg
Trial: 6357209
Drug: ASA 650
RxNorm normalized name: ASA 650 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 650 mg + codeine 60 mg
Trial: 6357209
Drug: ASA 650
RxNorm normalized name: ASA 650 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 650 mg
Trial: 20194044
Drug: Co-trimoxazole (CTM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (CTM) 48 mg/kg/day divided into two doses for 1 month
Trial: 14685867
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (BC) 60 g.day(‐1)
Trial: 9262268
Drug: HCG (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG (5000 IU) after Dexamethasone administration
Trial: 28926636
Drug: Per-unit dispensing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per-unit dispensing of antibiotics (experimental group)
Trial: 28926636
Drug: Traditional pre-packed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional pre-packed boxes of antibiotics (control group)
Trial: 27188987
Drug: Low AKG
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low AKG content (LAC, 10 mg AKGs)
Trial: 27188987
Drug: High AKG
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High AKG content (HAC, 20 mg AKGs)
Trial: 15882526
Drug: dTpa-IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa-IPV vaccine
Trial: 15882526
Drug: dTpa+IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa+IPV vaccine
Trial: 15882526
Drug: Td-IPV vaccine
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td-IPV vaccine
Trial: 11211195
Drug: IVIg (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (500 mg/kg/day for 7 days)
Trial: 11211195
Drug: Monoclonal anti-CD3
RxNorm normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal anti-CD3 (OKT3, 5 mg/day for 14 days)
Trial: 7522124
Drug: Combined postoperative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined postoperative radiation and chemotherapy
Trial: 25605189
Drug: Intravenous flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous flurbiprofen axetil and opioids
Trial: 25605189
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate sustained-release tablets
Trial: 15172863
Drug: 10-mL 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mL 1% lidocaine infusion
Trial: 15172863
Drug: 10 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 minutes after lidocaine infusion
Trial: 9790153
Drug: Alprazolam 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.125 mg twice a day
Trial: 7658064
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus monovalent reassortant vaccine (10^4 pfu)
Trial: 7658064
Drug: Tetravalent vaccine
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent vaccine (10^4 pfu)
Trial: 2651924
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg nightly
Trial: 1132949
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Primperan (20 mg metoclopramide, Lundbeck)
Trial: 1132949
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Metopram (20 mg metoclopramide, Leiras)
Trial: 22749947
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (4 g over 15 minutes followed by 16 g over 24 hours)
Trial: 17317046
Drug: Transdermal E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/NETA (25 microg E2 and 125 microg NETA applied every 3-4 days)
Trial: 17317046
Drug: Oral E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NETA (1 mg E2 and 0.5 mg NETA given daily)
Trial: 17317046
Drug: Transdermal E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/NETA
Trial: 15284540
Drug: Digital ETCO2/Spo2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital ETCO2/Spo2 monitoring during paramedic rapid sequence intubation (RSI) using midazolam and succinylcholine; rocuronium administered after confirmation of tube position.
Trial: 11300330
Drug: Anthracycline-based first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline-based first-line chemotherapy
Trial: 10224737
Drug: Behavioral choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral choice treatment (BCT)
Trial: 10224737
Drug: Traditional behavioral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional behavioral treatment (TBT)
Trial: 1839490
Drug: Teicoplanin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (6 mg/kg q24h i.v. after initial loading at 6 mg/kg q12h for three doses)
Trial: 1839490
Drug: Vancomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (15 mg/kg q12h i.v.)
Trial: 6476854
Drug: PUVA-UV-B therapy
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA-UV-B therapy administered twice weekly
Trial: 6476854
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of PUVA and UV-B
Trial: 31051059
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no HBO2 therapy)
Trial: 29314138
Drug: Lower insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower insulin dosages
Trial: 26965763
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid fortified milk (FM) providing 400 μg folic acid per day
Trial: 23681403
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy (cyclophosphamide-methotrexate-5-fluorouracil or doxorubicin-cyclophosphamide)
Trial: 15480981
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice a day plus omeprazole placebo once daily
Trial: 15480981
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg twice daily plus omeprazole 20 mg once daily
Trial: 10636525
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (2 g over 5 min followed by 16 g over 24 h)
Trial: 7924475
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline (loading dose followed by infusion)
Trial: 7924475
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal volume as loading dose and infusion)
Trial: 28466660
Drug: Percutaneous polidocanol
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous polidocanol injection (PPI)
Trial: 23496876
Drug: Lumbar spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar spinal manipulation therapy (SMT)
Trial: 21518837
Drug: Intravenous linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous linezolid at 600 mg twice daily
Trial: 21518837
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid at 600 mg twice daily
Trial: 21518837
Drug: Thrice-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily dosing of intravenous linezolid
Trial: 21518837
Drug: Thrice-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily dosing of oral linezolid
Trial: 8122021
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose aerosol (Nebuhaler)
Trial: 26291338
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive SIJ fusion with triangular titanium implants
Trial: 26291338
Drug: Crossover from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover from nonsurgical to surgical treatment
Trial: 16439047
Drug: F (226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F (226 microg F/ml as NaF)
Trial: 12548082
Drug: simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 80 mg/d
Trial: 12548082
Drug: atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 40 mg/d
Trial: 10911780
Drug: Mannitol (equiosmolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (equiosmolar solution)
Trial: 10911780
Drug: 0.9 N
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9 N Saline solution
Trial: 3891203
Drug: Moxalactam disodium
RxNorm normalized name: Moxalactam disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam disodium 2 g every 12 hours
Trial: 3891203
Drug: Gentamicin (3-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (3-5 mg/kg/day in three divided doses) and clindamycin phosphate 600 mg every six hours
Trial: 29032078
Drug: Pasireotide 10
RxNorm normalized name: pasireotide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 10 mg every 4 weeks for 12 months
Trial: 29032078
Drug: Pasireotide 30
RxNorm normalized name: pasireotide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 30 mg every 4 weeks for 12 months
Trial: 29032078
Drug: Pasireotide 10
RxNorm normalized name: pasireotide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 10 mg